From neuroprogression to neuroprotection: implications for clinical care

Michael Berk, Philippe Conus, Flavio P Kapczinski, Ana Cristina Andreazza, Murat Yucel, Stephen J Wood, Christos Pantelis, Gin Singh Malhi, Seetal Dodd, Andreas Bechdolf, G Paul Amminger, Ian B Hickie, Patrick D McGorry

Research output: Contribution to journalArticleResearchpeer-review

82 Citations (Scopus)


Bipolar disorder follows a staged trajectory in which persistence of illness is associated with a number of clinical features such as progressive shortening of the inter-episode interval and decreased probability of treatment response. ? This neuroprogressive clinical process is reflected by both progressive neuroanatomical changes and evidence of cognitive decline. ? The biochemical foundation of this process appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and oxidative stress. There is a growing body of evidence to suggest that these markers may differ between the early and late stages of the disorder. ? The presence of a series of tangible targets raises the spectre of development of rational neuroprotective strategies, involving judicious use of current therapies and novel agents. Most of the currently used mood stabilisers share effects on oxidative stress and neurotrophins, while novel potentially neuroprotective agents are being developed. These developments need to be combined with service initiatives to maximise the opportunities for early diagnosis and intervention.
Original languageEnglish
Pages (from-to)36 - 40
Number of pages5
JournalThe Medical Journal of Australia
Issue number4
Publication statusPublished - 2010
Externally publishedYes

Cite this